Adlai Nortye
ANL | NASDAQ
$10.03
-$0.58 (-5.47%)
At close: Nov 16, 2026, 4:00 PM ET
$10.03
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-5.47%
(1D)No price chart data available for 1D timeframe.
Rating
53.2
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #215/1021 (Top 21%)
Key Statistics
Market Data
Market Cap $532.39M
1D Range
9.80 11.00
52W Range
0.88 16.60
Valuation (TTM)
PE -5.14
PB 2.48
EV/EBITDA -15.57
Valuation (NTM)
Forward PE 5.06
Forward PEG 0.14
Price Target $32.00
Cash Flow
FCF Yield -10.9%
SBC Adj. FCF Yield -11.4%
SBC Impact -3.9%
Margins
Gross Margin 100.0%
Operating Margin -113.3%
FCF Margin -296.0%
Growth (CAGR)
Revenue 3Y | 5Y 150.0% |
-80.3%
Dil EPS 3Y | 5Y 64.7% |
3.7%
FCF 3Y | 5Y 8.0% |
-17.4%
Returns
ROA -9.1%
ROE -21.8%
ROIC -9.2%
Financial Health
Net Cash
$206.93M
Current Ratio 9.55
Interest Coverage -16.99
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide ...
Sector Healthcare
Industry Biotechnology
Employees 109
IPO Date Sep 29, 2023
Website www.adlainortye.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$32.00
Upside
+219.04%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ANL